Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trialsNonhlanhla N. Mkhize, Lynn Morris, Valerie Bekker et al.|PLoS Pathogens|2023Cited by 57
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresMichal Juraska, James I. Mullins, Hongjun Bai et al.|Proceedings of the National Academy of Sciences|2024Cited by 22
A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trialTomer Hertz, Carolyn Williamson, Murray G. Logan et al.|Vaccine|2016Cited by 18
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infectionJames I. Mullins, Carolyn Williamson, Wenjie Deng et al.|Nature Communications|2026Cited by 3
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention TrialsCarolyn Williamson, James I. Mullins, Lyle Curry et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1